Bilayer-Coated Oxybate Composition for Once-Nightly Low-Sodium Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing sodium oxybate formulations for narcolepsy treatment have high sodium content, leading to undesirable daily sodium intake, potential side effects, and abuse risks, while requiring twice-nightly dosing.

Innovation Solution

A once-nightly extended release oxybate powder for oral suspension (POS) with a blend of oxybate-containing multiparticulates having different release profiles, including immediate, extended, and Small Intestine Targeted Drug Coating System (SITCS) components, controlled by calcium chloride equivalents to minimize sodium content and achieve therapeutic plasma levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If sodium oxybate is used to treat narcolepsy, then therapeutic effect is achieved, but sodium intake increases and causes side effects

Engineering Contradiction:

Improvetherapeutic effectVSAvoidsodium intake and side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the harmful sodium component from the oxybate treatment by using calcium oxybate instead. The formulation removes sodium oxybate and replaces it with calcium oxybate, thereby eliminating the source of excessive sodium intake while preserving the therapeutic oxybate effect. This is achieved through ion exchange resin technology that enables calcium to replace sodium as the counterion.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the chemical parameter of the oxybate salt from sodium to calcium. By altering the cationic component from Na+ to Ca2+, the formulation maintains the active oxybate anion while changing the associated electrolyte profile. This parameter change reduces sodium content and modifies the osmotic and electrolyte characteristics of the formulation.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If high dose oxybate is administered, then narcolepsy symptoms are controlled, but abuse risk increases

Engineering Contradiction:

Improvesymptom controlVSAvoidabuse risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the oxybate delivery into multiple components with different release profiles. The formulation includes immediate release oxybate, extended release oxybate, and small intestine targeted delayed release oxybate. This segmentation allows for controlled plasma concentration profiles that achieve symptom control while reducing the risk of abuse by avoiding high peak concentrations.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent implements periodic action through extended and delayed release mechanisms. The oxybate is released in a controlled periodic manner throughout the night, with immediate release providing initial effect, extended release maintaining therapeutic levels, and delayed release providing sustained effect. This periodic delivery pattern reduces abuse potential compared to immediate high-dose administration.

Inventive Principle:

Principle #19Periodic action

3Reliability

If twice-nightly dosing is required, then therapeutic levels are maintained, but patient compliance decreases

Engineering Contradiction:

Improvetherapeutic levelsVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent merges multiple oxybate release functions into a single nighttime dose. By combining immediate release, extended release, and delayed release components in one formulation, the patent eliminates the need for twice-nightly dosing. The single dose provides sustained therapeutic levels throughout the night, improving patient compliance while maintaining efficacy.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent ensures continuity of useful action through extended and delayed release mechanisms that maintain therapeutic oxybate levels continuously throughout the night. The formulation provides uninterrupted therapeutic effect from initial dosing through morning, eliminating the gap that would require a second nighttime dose. This continuous action maintains symptom control while simplifying the dosing regimen.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation provides a desirable release profile with low sodium content, reducing adverse events, improving patient compliance, and eliminating the need for twice-nightly dosing.

Implementation Method 1

an anion exchange resin in a matrix

Methodology Applied

Scientific EffectIon exchange: Ion Exchange

Implementation Method 2

a pH-independent diffusion barrier coating layer which comprises a water-insoluble film-forming polymer

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 3

an outer pH-dependent polymer coating layer which dissolves at a pH greater than about 4.5

Methodology Applied

Scientific EffectpH-dependent dissolution: Solvation

Data Source

PatentUS12533314B2Low sodium oxybate once nightly composition

Publication Date: 2026.01.27 TRIS PHARMA INC

AI summary

Compositions providing a once-a-night dose of oxybate are provided. The compositions containing bilayer-coated oxybate anion exchange resin complex multiparticulates provide modified release of the oxybate for 5 to 8 hours post-dosing. Also provided are methods of treating patients in need thereof with pharmaceutical compositions containing the oxybate—anion exchange resin complex.